ARENSIA Exploratory Medicine is a privately owned company specialized in the performance of early patient trials: Phase I/Ib/IIa and PROOF OF CONCEPT studies in numerous patient populations, conducted in dedicated hospital based clinical pharmacology units in Central and Eastern Europe.

SPEED AND CAPABILITY MAKE US UNIQUE!

ARENSIA brings together large patient populations (incl. treatment naive) with year long know-how in exploratory clinical trials. The mix of resources and skills is highly potent: we are able to conduct the most complex studies, in patients, in a Phase I set-up.

The company has strategic, exclusive partnerships with reputed university and clinical hospitals in Romania, Republic of Moldova and Lithuania for exploratory development projects, which are conducted in compliance with all GCP principles typical of Western drug development:

3 units in Bucharest, Romania: focused on respiratory, respectively internal diseases & nephrology, and infectious diseases.
The regulatory approval timelines are 6 to 8 weeks.

1 unit in Chisinau, Republic of Moldova: focused on immunology, diabetes/metabolic, gastro-enterology, hepatology, urology, nephrology, infectious diseases HCV.
The regulatory approval timelines are 3 to 4 weeks.

1 unit in Vilnius, Lithuania: focused on cardiovascular, immunology, oncology, hepatology, nephrology.
The regulatory approval timelines are 6 to 8 weeks.

Our staff has proudly contributed to more than 200 projects in Phase I to III over the last 5 years, the majority performed for the top 15 pharmaceutical companies worldwide.

ARENSIA: YOUR RELIABLE PARTNER FOR PROOF OF CONCEPT / EARLY PATIENT STUDIES!